Literature DB >> 21855996

Anagrelide and cardiovascular events. Much ado about nothing?

Carlos Besses, Manuel Martínez-Sellés.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21855996     DOI： 10.1016/j.leukres.2011.07.031

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.

Authors:  Ruben A Mesa; Jean-Jacques Kiladjian; Srdan Verstovsek; Haifa Kathrin Al-Ali; Jason Gotlib; Heinz Gisslinger; Richard Levy; Andres Siulnik; Vikas Gupta; Mahmudul Khan; John F DiPersio; Mari McQuitty; John V Catalano; Deborah S Hunter; Laurent Knoops; Michael Deininger; Francisco Cervantes; Carole Miller; Alessandro M Vannucchi; Richard T Silver; Tiziano Barbui; Moshe Talpaz; Giovanni Barosi; Elliott F Winton; Estella Mendeson; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; William Sun; Victor Sandor; Hagop M Kantarjian; Claire Harrison
Journal:  Haematologica       Date:  2013-08-02       Impact factor: 9.941

2.  Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Authors:  Tomoki Ito; Yoshinori Hashimoto; Yasuhiro Tanaka; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Akiko Hashimoto; Toshinori Kondo; Hiromi Omura; Isaku Shinzato; Takayuki Tanaka; Shosaku Nomura
Journal:  Eur J Haematol       Date:  2019-06-17       Impact factor: 2.997

3.  Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions.

Authors:  Manuel Martínez-Sellés; Tomás Datino; Lourdes Figueiras-Graillet; Joubert G Gama; Christopher Jones; Richard Franklin; Francisco Fernández-Avilés
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.